Keymed Biosciences Inc. (HKG:2162)
72.50
-2.75 (-3.65%)
Jul 30, 2026, 3:40 PM HKT
Keymed Biosciences Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Keymed Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $96.12. The average 1-year stock price forecast is 32.58% higher than the current stock price, while the lowest is $85.01 (+17.26%) and the highest is $105.61 (+45.67%).
Price Target: $96.12 (+32.58%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Keymed Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 6 | 7 | 8 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 9 | 10 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Guotai Haitong No rating | Guotai Haitong | Buy Maintains $138.91 | Buy | Maintains | $138.91 | +91.60% | Jul 10, 2026 |
Unknown Analyst Shenwan Hongyuan No rating | Shenwan Hongyuan | Buy Maintains $89.47 | Buy | Maintains | $89.47 | +23.41% | May 28, 2026 |
Unknown Analyst Morgan Stanley No rating | Morgan Stanley | Buy Maintains $97.00 | Buy | Maintains | $97.00 | +33.79% | May 28, 2026 |
Unknown Analyst KeyBanc No rating | KeyBanc | Buy Maintains $87.31 | Buy | Maintains | $87.31 | +20.43% | Apr 4, 2026 |
Unknown Analyst Huatai Securities No rating | Huatai Securities | Buy Maintains $91.08 → $91.13 | Buy | Maintains | $91.08 → $91.13 | +25.70% | Mar 30, 2026 |
Financial Forecast
Revenue This Year
2.51B
from 716.31M
Increased by 250.90%
Revenue Next Year
2.15B
from 2.51B
Decreased by -14.66%
EPS This Year
2.70
from -1.81
EPS Next Year
0.56
from 2.70
Decreased by -79.05%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.